By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists agreed that Axon's transition to a high-margin SaaS business model is positive, but they have differing views on the stock's valuation and the risks associated with its dependence on public-sector contracts and AI-driven surveillance tools.
Risk: Concentration risk on public-sector contracts and regulatory scrutiny of AI surveillance tools could force faster multiple re-rating than earnings justify.
Opportunity: Axon's high net revenue retention and recurring software spend could lock in law enforcement budgets.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Axon Enterprise, Inc. (NASDAQ:AXON) was among the stocks on which Jim Cramer gave his opinion, as he warned that increased AI-related spending might cause near-term headwind for stocks. Mentioning that they own shares of the stock, a caller asked if they should buy more, sell, or hold. In response, Cramer said:
No, I want you to hold it. I want you to hold it. You know, look, the only reason I don’t tell you to sell is because I know that the product is, you know, their products are doing well, but the problem is it sells at a very high price to earnings multiple. Now, people don’t understand the M. This is why I wrote How to Make Money in Any Market. The M is the secret sauce, and the M’s too high, and people are selling that because of it.
Photo by Artem Podrez on Pexels
Axon Enterprise, Inc. (NASDAQ:AXON) develops and sells TASER devices, body and fleet cameras, and software solutions that help law enforcement capture, store, and manage digital evidence. During the May 15 episode, a caller noted that they have been holding the stock since 2015, when the share price was $34 on Cramer’s suggestion, and inquired about it. Cramer replied:
Well, they had, you know, Axon was on today. I thought they acquitted themselves, which is why I think why the stock was up three bucks. I have been, we were very worried about Motorola competition when we met with them when we were up at Harvard Business School. I am still concerned about that, and I still think that this market does not like high multiple stocks, and Axon is a high multiple stock.
While we acknowledge the potential of AXON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years** **
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Axon can sustain a durable growth path through software and AI-enabled analytics, justifying a re-rating despite a lofty valuation."
News highlights a cautious take on AXON due to high P/E. But Axon's business mix isn’t just hardware sales; Evidence.com and other software subscriptions generate more durable, recurring revenue that tends to compound as agencies expand digital evidence workflows. AI spending could accelerate adoption of smarter body cameras and faster analytics, potentially expanding the TAM beyond hardware cycles. Moreover, multi-year public-sector contracts and federal grant programs can provide visibility and upside optionality that a simple P/E multiple misses. The missing context includes current gross and operating margin trajectory, cash flow, backlog, and guidance; competition from Motorola Solutions; and the risk that AI budgets wobble and the stock re-prices quickly if discretionary spending tightens.
Bearish counterpoint: AXON's premium multiple largely reflects optimism about software-like growth in a government-driven cycle; if AI spending softens or procurement delays bite, the premium may contract faster than earnings can grow, and competition from MSI could erode pricing power.
"Axon’s valuation is justified by its transition into a mission-critical SaaS ecosystem, making it more of a software play than a hardware manufacturer."
Cramer’s focus on the P/E multiple misses the structural shift in Axon’s business model. While he fixates on the 'M' (multiple), he ignores that Axon has transitioned from a hardware-centric Taser manufacturer to a high-margin SaaS powerhouse via its Evidence.com platform. With net revenue retention consistently above 120%, the company is effectively locking in law enforcement budgets as recurring software spend. While a forward P/E north of 70x is undeniably rich, it reflects a dominant market position with virtually no churn. The real risk isn't the valuation—it’s the regulatory and political sensitivity of their AI-driven surveillance tools, which could face sudden, non-market-driven headwinds that no valuation model can fully price in.
If law enforcement agencies face severe budget contractions due to broader macroeconomic pressures, Axon’s 'sticky' software revenue could face unexpected cancellation or non-renewal cycles.
"AXON is operationally sound but structurally vulnerable to multiple compression if growth disappoints or the market's appetite for high-P/E names weakens further."
Cramer's warning is about valuation, not fundamentals—he explicitly says products are 'doing well' but the multiple is 'too high.' This is a timing/risk-management call, not a conviction short. The real issue: AXON trades at ~65x forward P/E (vs. S&P 500 ~19x), justified only if growth sustains at 25%+ CAGR. Cramer's 'hold' is actually cautious—he won't recommend selling because the business works, but he won't chase it either. The article's editorial push toward 'better AI stocks' is noise; the substance is that AXON is priced for perfection in a market rotating away from high-multiple names.
If AXON's TAM (law enforcement software + hardware ecosystem) is genuinely expanding 30%+ annually and switching costs are high, today's multiple could compress to 45x within 18 months on earnings growth alone—making the 'too expensive' thesis premature and a hold a missed opportunity.
"Cramer's multiple warning on AXON is credible but incomplete without data on whether Motorola share gains or budget cuts are actually materializing."
Cramer's hold call on AXON underscores market distaste for high multiples even when products like TASERs and evidence software are performing, with Motorola competition flagged as a lingering threat from prior meetings. The piece pairs this with a generic AI-spending warning but skips any detail on AXON's actual earnings trajectory, contract wins, or how its own AI features in cameras might offset valuation pressure. Investors are left to infer that multiple compression is the dominant near-term risk without evidence on whether growth can outpace it or if law-enforcement budgets are already slowing.
AXON could still command its premium if recurring software revenue accelerates faster than peers, rendering the current multiple sustainable rather than excessive.
"Axon's revenue concentration and procurement cycles in the public sector could trigger outsized re-rating risk even with strong retention."
Two gaps in Gemini's case: NRR >120% is impressive, but Axon's revenue is unusually dependent on a handful of public-sector contracts. High retention can disguise renewal risk if budgets tighten or political priorities shift; a major agency delay or cancellation could hit ARR before growth assets kick in. That concentration risk plus ongoing regulatory scrutiny of AI surveillance could force faster multiple re-rating than earnings justify, even if gross software margins stay strong. Valuation remains sensitive to procurement cycles.
"Persistent high interest rates pose a direct threat to Axon's net margins by increasing the cost of financing their aggressive R&D and hardware-heavy growth strategy."
Claude, you hit the nail on the head regarding the 'priced for perfection' trap, but everyone is ignoring the capital expenditure cycle. Axon isn't just selling software; they are funding massive R&D for AI-integrated hardware. If interest rates remain 'higher for longer,' the cost of carrying that debt to fuel growth will erode net margins. We aren't just looking at multiple compression; we are looking at a potential earnings miss if interest expenses outpace software scalability.
"AXON's balance sheet doesn't support a debt-driven earnings miss; procurement delays and AI feature execution are higher-order risks."
Gemini's debt-cost argument assumes AXON is highly leveraged, but the company carries minimal net debt (~$200M against $3B+ market cap) and generates strong FCF. Interest headwinds are real for growth-stage firms, but AXON's balance sheet doesn't support the 'earnings miss' scenario Gemini sketched. The real capex risk is R&D burn if AI features underdeliver—not debt service. ChatGPT's concentration risk on public-sector contracts is the sharper threat.
"Contract concentration plus AI delays creates faster re-rating risk than debt costs for AXON."
Gemini, the debt-service risk you flag doesn't hold—AXON's low net debt and FCF, as Claude noted, limit interest pressure. The sharper unaddressed link is how ChatGPT's public-sector contract concentration could interact with AI rollout delays: if agencies slow renewals amid surveillance scrutiny, ARR growth stalls before R&D pays off, accelerating multiple compression beyond what earnings alone can offset.
The panelists agreed that Axon's transition to a high-margin SaaS business model is positive, but they have differing views on the stock's valuation and the risks associated with its dependence on public-sector contracts and AI-driven surveillance tools.
Axon's high net revenue retention and recurring software spend could lock in law enforcement budgets.
Concentration risk on public-sector contracts and regulatory scrutiny of AI surveillance tools could force faster multiple re-rating than earnings justify.